• Botanical Oils are one of the fastest growing segments in nutraceuticals
  • Management Team with superb credentials.
  • Favorable capital structure
  • Strategic Investor backstops acquisition

The market reaction to the acquisition of Eqova Life Sciences was very favorable trading up 132% on Friday.  The size of the Cannabinoid (CBD) products market is expected to reach $2.1 Billion by 2020 according to the Hemp Business Journal.  This means there is still a lot of opportunity for innovative startups like Eqova.  When companies enter a market that is growing so large and so fast, entrepreneurs can lose sight of their focus.  The pending acquisition of Eqova Life Sciences by Grey Cloak Technology (GRCK) due to close on October 10th seems like an ideal union that will provide capital markets liquidity to a startup company focused on the medical practitioner market.  The question on investor’s minds is how well can they execute on their business model and is it viable?  After conducting a little due diligence the answer appears to be in the team they assembled.  This team seem to be laser focused in targeting the niche market of medical practitioners that buy everything from nutraceuticals to cannabis.

Eqova Management

Patrick Stiles, the head of Eqova Life Sciences, is an industry veteran in the supplement industry.  His background is primarily in psychotropic therapies which makes him ideally suited for the hemp oil market.  For those that don’t have a dictionary handy, psychotropic means he is an expert in designing supplements that deal with a person’s mental state.  He was co-founder and CEO of Zen Life Supplements for over 6 years and was responsible for all facets of the operation including marketing and at its height had upwards of $1 mill in ad budget spent in just digital media.   The marketing background he offers the new company is a unique skillset that encompasses a consultative approach to direct marketing in a highly competitive supplement industry.  This is exactly what he was doing for years at Zen Life but he had to face the headwinds of distinguishing the products from all the other supplements out there.  The laser focus on Hemp Oil allows him to leverage all the positive press surrounding its uses and fold this into an aggressive growth plan that targets medical practitioners.  He was also involved in Thrive Science another small startup supplement company.   This background and entrepreneurial spirit that he brings to the new company just serves to underscore the old adage that you bet on the jockey not the horse.

He is not alone in this endeavor, Matt Grabau will be responsible for the sales and distribution of the product.  Matt is an all-star on his own account and brings a wealth of experience. For the last 12 years, he’s headed up sales for some of the largest practitioner lines of supplements in the country. His team at Rocky Mountain Pro Nutrients focuses on personalized medicines and giving medical practitioners the toolkit they need to help their patients.  Him and his direct reports have been selling $5 million annually while dealing with men’s and women’s health issues, immune health, sports nutrition, antioxidants, detoxification, cardiovascular, and blood sugar to name a few.
The convergence of these 2 industry veterans is no mistake because they can leverage their relationships to build a very large distribution force from scratch and effectively manage the growth.  It is conceivable that Patrick will be focused on logistics, operations, and marketing while Matt leads the sales channels.  They seem to be ramping up sales efforts quite nicely with over 10+ jobs posted on Zip Recruiterand Linked in looking for CBD sales reps.  Getting sales seems to be both of these managers forte and that focus to drive sales is what creates the true value in this company. 

Exponential Sales Growth Potential

Doing some napkin math it’s conceivable that with 10 sales reps they might be able to do about $1 million per sales representative annually.  This metric comes from what an average outside sales pharmaceutical rep could produce to a pharmacy in a given year.  This sales team could drive total sales close to $10 mil in the first year.  With at least 50% Gross Margins on hemp oil it’s not unreasonable to see $5 mil in gross profit the first year.

Favorable Market Structure

The company is on OTC markets listed under Pink Current Information and fully reporting with the SEC.   From the latest 10-Q they had 25,319,572 shares issued and outstanding.  Their fraud analytics subsidiary is continuing to produce revenue but it’s uncertain if they are profitable.  The salient point about the revenue is that GRCK is not a shell company.  The company is active and has been making progress on the balance sheet and has cleaned up some of its convertible debt and went from $405,097 to $349,062 in the past 6 months according to the last quarterly filing.  They have been fully reporting since 2015 so a natural progression to look for might be an uplisting, now that money and revenue seem to be in place.

Large Strategic Investor

There was a 13-G filing by Oakmore Opportunity Fund LLP on Sept 26, 2017 where they filed that they owned 4,657,247 shares of common stock or 9.9% of the stock which puts the new share count at 46,619,089.  The timing of this filing suggests a couple of things.  It appears that they likely bought out the remaining debt from the noteholder and might have put additional capital in the company to scale up operation.  Oakmore doesn’t seem to be a very large fund with its only other holding in Wisdom Homes of America, Inc. (WOFA) but it seems they are very selective and that should bode well for GRCK shareholders.  It’s not hard to connect that the activity in the past couple of days has been driven by fund interest in a great growth story.

Earnings Growth Acceleration

The details of the deal remain unknown but it’s not hard to conservatively speculate that management might hold has much as 25% percent of the company which could potentially drive the share count as high at 58 million.  Assuming share count goes to 58 million, and it might not even be that dilutive because they might structure in some options based on performance investors could be looking at roughly $.16 in eps per share assuming this capital structure and sales momentum.  Investor’s should keep in mind that this is a hypothetical scenario and should wait until early October to see what the terms of the deal are and react accordingly.

Investment Summary

GRCK with its acquisition of Eqova Life Sciences might have stuck paydirt.  What you essentially have are two industry veterans, powerhouses in their own right, coming together to sell the hottest selling product in the nutraceutical space utilizing their industry acumen and contacts.  The question yet to be answered is do they have the right plan to rapidly scale the business?  Their industry experience seems to be perfectly aligned to target the commonly ignored practitioner market.  A strategic investor with startup capital seems to be in place and the dilution has come to an end setting up the perfect storm for stock appreciation.  With potential sales news on the horizon, and the build out of product labels and inventory this could be a fun story to watch unfold. With 46 mil shares outstanding and a market cap of $1.15 mil this seems undervalued given the potential of this team.  It’s way too early in the story to set price targets but the earnings potential of this business is amazing compared to the last acquisition target they were looking at when the stock was trading at $.15/share.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. Full details about which can be found in our full disclosure, which can be found here, http://emerginggrowth.com/4725-4739/. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.